Wayfinding Financial LLC Sells 41 Shares of Eli Lilly and Company (NYSE:LLY)

Wayfinding Financial LLC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 3.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,047 shares of the company’s stock after selling 41 shares during the quarter. Wayfinding Financial LLC’s holdings in Eli Lilly and Company were worth $864,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of LLY. WestEnd Advisors LLC raised its stake in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after acquiring an additional 21 shares during the period. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares during the period. Mascagni Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $43,000. Prudent Man Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $48,000. Finally, O Brien Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after purchasing an additional 12 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.0%

LLY stock opened at $779.60 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company’s 50 day moving average is $773.61 and its 200 day moving average is $799.96. The stock has a market cap of $738.85 billion, a price-to-earnings ratio of 63.43, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. Eli Lilly and Company’s quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.58 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their target price for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price objective on the stock. UBS Group decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Finally, Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.